- Evolus (EOLS, Financial) projects 2025 net revenues between $295 million and $305 million, marking an 11% to 15% increase over 2024.
- The company plans to launch new products, including Evolysse Sculpt in 2026 and Evolysse Lips in 2027.
- Evolus aims for sustainable profitability by 2026, with a target of a 20% non-GAAP operating income margin by 2028.
Evolus (EOLS) has reaffirmed its financial guidance for 2025, expecting total net revenues to range from $295 million to $305 million, indicating an 11% to 15% increase over projected 2024 figures. The company's Evolysse injectable HA gels are anticipated to contribute 10% to 12% to the full-year revenue for 2025. Additionally, Evolus forecasts full-year non-GAAP operating expenses between $208 million and $213 million.
The company has outlined a strategic timeline for launching new products, with Evolysse Sculpt set to debut in the U.S. in 2026, followed by Evolysse Lips in 2027. By 2028, Evolus aims to achieve total net revenue of $700 million and plans to update its long-term financial outlook in early 2026, after reassessing market conditions.
Looking ahead, Evolus expects to achieve positive non-GAAP operating income, projected between $5 million and $7 million, by the fourth quarter of 2025. The company is also on track for sustainable profitability starting in 2026. Moreover, Evolus plans a limited release of Estyme in Europe through a select group of physician partners, with a broader rollout targeted for the first half of 2026. By 2028, Evolus aims to reach a 20% non-GAAP operating income margin by efficiently utilizing its existing resources.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.